GynecologyGynecology2079-56962079-5831Consilium Medicum28556Research ArticleEvaluation of mental and emotional state of patients with polycystic ovary syndrome on the background of hormonal contraceptionPestrikovaT Iutyp50@rambler.ruIurasovaE Aurasoaea@yandex.ruSukhonosovaE Lsuhonosova.ekaterina@mail.ruFar Eastern State Medical University of the Ministry of Health of the Russian Federation15082016184495309042020Copyright © 2016, Consilium Medicum2016Goal. The study of changes in mental and emotional state in patients with polycystic ovarian syndrome before you start taking a hormonal contraceptive containing estradiol valerate (E2V) in combination with dienogest (DNG) in dynamic mode and after 12 months against a background of continued administration. Materials and methods. The study included 36 patients in need of contraception (aged 22 to 31 years), with the presence of symptoms of hyperandrogenism and menstrual irregularities. All patients completed self-assessment questionnaires for mental and emotional state before the reception and at 12 months in patients receiving hormonal contraceptive. Results. Hormonal contraceptive (E2V in combination with DTG) used in a continuous dynamic mode, has a positive therapeutic effect against clinical manifestations of hyperandrogenism and reproductive status of patients with PCOS. The therapeutic effect in combination with E2V dienogest was to authentic decrease in severity of symptoms of hyperandrogenism (acne, fat skin). In addition, in patients receiving hormonal contraceptive it noted improvements in mental and emotional state of patients with polycystic ovary syndrome, which is caused by a decrease in symptoms of hyperandrogenism, and the normalization of body weight (by diet).polycystic ovary syndromehyperandrogenismestradiol valerate combined with dienogestassessment of mental and emotional stateсиндром поликистозных яичниковгиперандрогенияэстрадиола валерат в комбинации с диеногестомоценка психоэмоционального состояния[Legro R.S, Arslanian S.A, Ehrmann D.A et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014.][Rotterdam ESHRE/ASRM - Sponsored PCOS consensus workshop group. (2004) Revised 2003 consensus on diagnostic criteria and long - term health risks related to Polycystic Ovary Syndrome (PCOS). Hum Reprod 2004; 19: 41-7.][Роговская С.И. Вульвовагинальный и цервикальный эпителий и гормональные средства. Status praesens. 2014; 6 (17): 41-7.][Fauser B.C.J.M, Tarlatzis B.C, Rebar R.W et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS. Fertil Steril 2012; 97: 28-38.][Зеленина Н.В., Бескровных С.В., Молчанов О.Л. Синдром поликистозных яичников - проявление социально - адаптационного напряжения. Рос. вест. акушера гинеколога. 2012; 3: 67-74.][Francesco De Seta at al. Effect of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol 2014; 30 (11): 830-5.][Манухин И.Б., Тумилович Л.Г., Геворкян М.А. Клинические лекции по гинекологической эндокринологии. М.: ГЭОТАР - Медиа, 2014.][Evidence - based Methodology Workshop on Polycystic Ovary Syndrome. December 3-5, 2012. http://prevention.nih.gov/workshops/2012/pcos/.][Jensen J. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Exp Opin Pharmacother 2010; 11: 1147-57.][Parke S, Nahum G.G, Mellinger U, Junge W. Metabolic effects of a new four - phasic oral contraceptive containing estradiol valerate and dienogest. Obstet Gynecol 2008; 111: 15S.][Bitzer J, Heikinheimo O, Nelson A.L et al. Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstet Gynecol Survey 2015; 70 (2): 115-30.][Лизнева Д.В., Синицына А.И. Фундаментальные и клинические аспекты использования натуральных эстрогенов в составе современной комбинированной гормональной контрацепции. Проблемы репродукции. 2012; 18 (5): 22-6.][Burrows L.J, Basha M, Goldstein A.T. The effect of hormonal contraceptives of female sexuality. a review. J Sex Med 2012; 9 (9): 2213-23.][Caruso S, Agnello C, Romano M et al. Preliminary study on the effect of four - phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med 2011; 8 (10): 2841-50. [PMID:21810188.].][Costantino Di Carlo et al. Effect of estradiol valerate and dienogest on quality of life and sexual function according to age. Gynecol Endocrinol Early Online 2014; 1-4.][Davis S.R, Bitzer J, Giraldi A et al. Change to either a nonandrogenic or androgenic progestin - containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive - associated sexual dysfunction. J Sex Med 2013; 10 (12): 3069-79. [doi: 10.1111/jsm.12310. Epub 2013 Sep 12. PMID:24034466.].][Palacios S, Wildt L, Parke S et al. Efficacy and safety of a novel oral contraceptive based on estradiol (estradiol valerate/dienogest): a phase III trial. Eur J Obstet Gynecol Reprod Biol 2010; 149; 57-62.]